Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FCARH 143

Next Previous
X
Search
Drug Profile

FCARH 143

Alternative Names: Autologous anti-BCMA-CAR-expressing CD4+/CD8+ T lymphocytes - Juno Therapeutics; BCMA CAR-CD4+/CD8+ T cells; BCMA-specific CAR-expressing CD4+/CD8+ T lymphocytes; FCARH143

Latest Information Update: 28 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 08 Jan 2024 Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics terminates a phase-I trial in Multiple myeloma in USA (PO) due to SRC low accrual policy (NCT03502577)
  • 22 Mar 2022 Juno Therapeutics and Fred Hutchinson Cancer Research Center completes a phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03338972)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top